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Innovation at the
Food and Drug Administration’s
Device Center*
William H. Maisel, MD, MPH
Silver Spring, Maryland
Each year, millions of American patients benefit from
innovative medical devices that reduce suffering, treat pre-
viously untreatable conditions, extend lives, and improve
public health. The Food and Drug Administration (FDA)
is committed to assuring that patients have timely access to
important new technologies and next-generation medical
devices without compromising safety. Recently, the FDA’s
Center for Devices and Radiological Health (CDRH) has
taken a number of actions to encourage innovation, stream-
line regulatory and scientific device evaluation, and expedite
the delivery of novel, important, safe, and effective medical
devices to patients.
See page 790
In fact, CDRH has started implementing a new system-
atic approach to medical device oversight—one that not
only continues to focus on protecting public health by
assuring that devices are safe and effective, but also focuses
on promoting public health by facilitating device innovation.
This new approach requires that we move away from the
traditional misperception that safety and innovation are
incompatible. Rather than focus on more regulation or less
regulation, we focus on smart regulation—how to effectively
achieve both aspects of our mission as both a regulator and
a facilitator. The FDA must help create a regulatory
environment that allows innovation to thrive by eliminating
undue regulatory obstacles and assuring consumer confi-
dence that medical technology in the United States is safe
and effective. Evidence-based assessments of safety and effec-
tiveness and the facilitation of innovation are complementary,
mutually supporting aspects of our mission to protect and
promote public health.
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Center for Devices and Radiological Health, Food and Drug Adminis-t
ration, Silver Spring, Maryland. Dr. Maisel is the Deputy Director for Science and
hief Scientist at FDA’s Center for Devices and Radiological Health.In this issue of JACC: Cardiovascular Interventions, Kru-
coff et al. (1) make several suggestions for strengthening the
medical device ecosystem to gain efficiencies in product
evaluation and leverage the experience, expertise, and
unique role of medical professional societies.
A changing paradigm. As medical devices become increas-
ngly complex, we recognize that the responsibility of
ssuring the safety and effectiveness of devices resides, not
nly with the FDA, but also with industry, practitioners,
nd patients. Although the FDA has a world-class medical
evice scientific staff, it is unrealistic to expect us to have all the
ecessary expertise and experience, particularly in the review of
merging scientific fields and pioneering technologies.
For this reason, in October 2011, we began to pilot a new
etwork of Experts Program to serve as a resource for our
taff in better understanding scientific fields with which our
eviewers might not be immediately familiar. Collaboration
greements govern the relationship and exchange of ideas
nd information between CDRH staff and the several
rofessional healthcare societies, including the American
ollege of Cardiology (ACC), that constitute the Network
f Experts pilot program. The Network provides the FDA
ith a fast and efficient mechanism to exchange knowledge
ith world-class scientific experts on an as-needed basis.
Start early and collaborate often. In addition to proactively
ollaborating more often and more efficiently with outside
xperts, we believe there are other changes we can make to
peed the review of medical devices that address unmet
ublic health needs. The CDRH’s Innovation Pathway is a
ew way of doing business within our existing regulatory
ramework, one that could yield significant benefits to
atients in the United States by giving them first-in-the-
orld access to innovative medical devices of public health
mportance.
The Innovation Pathway is an evolving system designed to
elp safe and effective, breakthrough medical products reach
atients in a timely manner. The Pathway ultimately aims to
horten the overall time and cost it takes for the develop-
ent, assessment, and review of medical devices, and to
mprove how CDRH staff and innovators work together.
By engaging with innovators much earlier, more collab-
ratively, and in new ways, we believe we can reduce the
ime and cost of the entire process of bringing safe and
ffective technologies to patients more quickly. In April of
his year, the CDRH launched the second version of the
nnovation Pathway, called “Innovation Pathway 2.0.”
Innovation Pathway 2.0 offers new and modified tools
nd methods to deepen the collaboration between the
DRH and innovators early in the process, prior to pre-
arket submission, with the goal of making the regulatory
rocess more efficient and timely.
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798also apply to other technologies to enhance all of our device
pre-market programs.
First in the world: it matters. Recently, the CDRH revised
ts mission and vision statements to explicitly reflect the
mportance of integrating innovation and safety as comple-
entary parts of our public health mission. Patients
emain—and will always remain—the core of our mission,
hich is to protect and promote the public health.
Our vision is ambitious—that patients in the United
tates have access to high-quality, safe, and effective medical
evices of public health importance first in the world. This
ision recognizes that delaying access to devices that bring
mportant healthcare advances to patients has a public
ealth cost—just as permitting the marketing of unsafe or
neffective products does. Assessing the benefits and risks of
ew technologies is the fundamental calculus that serves as
he underpinning of good decision making.
Earlier this year, the CDRH released our first guidance
n the principal factors considered in the assessment of
enefit–risk—the foundation of our device approval deci-
ions. These factors include, not only the type and magni-
ude of the clinical benefits and adverse events a patient may
xperience, but also explicit consideration of the severity of
he underlying disease or condition, the availability of alterna-
ive treatments or diagnostics options, the novelty of the
echnology, and patients’ tolerance for risk and perspective
n benefit. We have also worked to create mechanisms for
ore efficient post-market surveillance of important new
echnologies so that the benefits and risks of novel device
herapies can be better defined during real-world use. For
xample, the Transcatheter Valve Therapy (TVT) Registry,
ill serve as the data collection platform for the post-market
tudy of the Edwards Lifescience Sapien Transcatheter
eart Valve, the first FDA-approved transcatheter aortic
alve therapy as well as future transcatheter valve devices.
he TVT Registry was formed through collaboration of the
CC (through the National Cardiovascular Data Registry),
he Society of Thoracic Surgeons, the Centers for Medicare
nd Medicaid Services, and the FDA.
The CDRH has also announced new policies for facili-
ating the conduct of early feasibility studies, including
rst-in-human trials, for medical devices in the United
tates while maintaining appropriate patient protections.he policies are predicated on the idea that appropriately
onducted early clinical experience with investigational
edical devices can result in better-designed devices that
each patients sooner. These proposed approaches give
nvestigators and the FDA device reviewers more flexibility
o start investigational device human studies sooner, and
nce a study has begun, efficient ways to support iterative
odifications to devices or study designs. Conducting safe,
arly feasibility studies in the United States means that
linicians get early experience with new technology, inno-
ators have greater incentives to study their devices first in
he United States, and patients may benefit more quickly.
Challenges and opportunities. Although the FDA has un-
ertaken a number of activities to facilitate medical device
nnovation to help bring safe, effective, high-quality, trans-
ormative devices to patients more quickly, we recognize
hat there are additional opportunities. Pre-competitive
ollaborations, modernization of post-market surveillance,
ore efficient use of post-market and international device-
elated clinical data and electronic health information, and
treamlining the conduct of clinical trials offer promise and
ill require broad device stakeholder input and collabora-
ion to succeed. In the end, regulators, industry, patients,
he clinical community, and the public at large all want the
ame thing—for patients to have timely access to high-
uality, safe, effective important new technologies and
ext-generation medical devices.
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